STOCKHOLM, Sweden, Aug. 11, 2005 (PRIMEZONE) -- Active Biotech:
-- All projects progressing in accordance with planned milestones
-- Issue totaling approximately SEK 169 M completed -- oversubscribed
by 43 percent
-- Exercise of option to repurchase research facility in Lund
-- Net sales: SEK 5.8 M (30.4)
-- Operating loss: SEK 100.5 M (loss: 97.0)
-- Loss after tax: SEK 110.3 M (loss: 76.6)
-- Loss per share for the period: SEK 3.27 (loss: 2.27)